Effect of new oral anticoagulants on platelet indices in non-valvular atrial fibrillation patients.

Effect of new oral anticoagulants on platelet indices in non-valvular atrial fibrillation patients. Herz. 2019 Aug 14;: Authors: Duzen IV, Oguz E, Cekici Y, Yavuz F, Vuruskan E, Sincer I, Poyraz F, Alıcı H, Yuksek U, Demirtas AO, Sucu M Abstract New-generation oral anticoagulants (NOACs) are now preferred as a first-line treatment in the management of atrial fibrillation for prevention of thromboembolic complications. Mean platelet volume (MPV), one of the indicators of increased platelet activity, is also associated with an increased stroke risk in atrial fibrillation patients. The aim of this study was to evaluate changes in MPV, platelet distribution width (PDW) and plateletcrit following use of NOACs. The study included 116 patients with non-valvular atrial fibrillation without previous NOAC use. Complete blood counts, biochemical analyses and echocardiography were performed for all patients. No significant differences were observed in MPV or other platelet indices at 6 months compared to baseline. Our results indicate that MPV and other platelet indices are not affected by NOAC use in non-valvular atrial fibrillation patients. PMID: 31414189 [PubMed - as supplied by publisher]
Source: Herz - Category: Cardiology Tags: Herz Source Type: research

Related Links:

Authors: Lowres N, Giskes K, Hespe C, Freedman B Abstract Atrial fibrillation (AF) is a significant risk factor for avoidable stroke. Among high-risk patients with AF, stroke risk can be mitigated using oral anticoagulants (OACs), however reduction is largely contingent on physician prescription and patient persistence with OAC therapy. Over the past decade significant advances have occurred, with revisions to clinical practice guidelines relating to management of stroke risk in AF in several countries, and the introduction of non-vitamin K antagonist OACs (NOACs). This paper summarises the evolving body of researc...
Source: Korean Circulation Journal - Category: Cardiology Tags: Korean Circ J Source Type: research
Condition:   Pattern of Non Valvular Atrial Fibrillation Intervention:   Device: echocardiography Sponsor:   Assiut University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Atrial Fibrillation;   Atrial Flutter;   Stroke;   Cardiac;   Heart Failure;   Arrhythmia Interventions:   Behavioral: SDMT;   Behavioral: Usual Care Sponsors:   Stanford University;   American Heart Association;   Boston University;   East Carolina University;   Ochsner Health System;   The Cleveland Clinic Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Pattern of Non Valvular Atrial Fibrillation Intervention:   Device: echocardiography Sponsor:   Assiut University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Atrial Fibrillation;   Atrial Flutter;   Stroke;   Cardiac;   Heart Failure;   Arrhythmia Interventions:   Behavioral: SDMT;   Behavioral: Usual Care Sponsors:   Stanford University;   American Heart Association;   Boston University;   East Carolina University;   Ochsner Health System;   The Cleveland Clinic Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
In this study, we sought to develop new and simpler models for LAAT prediction in chronic nonvalvular atrial fibrillation. The study enrolled 144 patients with chronic nonvalvular atrial fibrillation who underwent transesophageal echocardiography for LAAT detection. We examined the association of LAAT incidence with the CHA2DS2-VASc score and echocardiographic parameters pertaining to the left atrium (LA), including diameter, volume index, strain, and strain rate measured on speckle tracking echocardiography. LAAT was found in 24.3% of patients (39/144). The following parameters had good diagnostic performance for LAAT: LA...
Source: Cardiology Research and Practice - Category: Cardiology Authors: Tags: Cardiol Res Pract Source Type: research
In conclusion, the practice of stroke neurologists is consistent with and supports the available evidence from observational studies on the time of initiation of NOACs. Our findings provide a guide for clinicians who manage nvAF-related stroke until more robust evidence from randomized controlled trials is available. PMID: 31531241 [PubMed]
Source: Neurology Research International - Category: Neurology Tags: Neurol Res Int Source Type: research
Background: Optimal timing to initiate anticoagulation after acute ischemic stroke (AIS) from atrial fibrillation (AF) is currently unknown. Compared to other stroke etiologies, AF typically provokes larger infarct volumes and greater concern of hemorrhagic transformation, so seminal randomized trials waited weeks to months to begin anticoagulation after initial stroke. Subsequent data are limited and non-randomized. Guidelines suggest anticoagulation initiation windows between 3 and 14 days post-stroke, with Class IIa recommendations, and level of evidence B in the USA and C in Europe.Aims: This open-label, parallel-group...
Source: Frontiers in Neurology - Category: Neurology Source Type: research
ConclusionsThe key determinants of the Bleeding Ratio among anticoagulated AF patients are age, prior thromboembolic and bleeding episodes. The study could support identification of AF patients who need additional effort to increase their acceptance of a life-long OAC therapy.
Source: Canadian Journal of Cardiology - Category: Cardiology Source Type: research
Conclusions: The use of DOACs is a reasonable alternative to vitamin K antagonists in AF patients with CHADS2 score ≥3, advanced age, and HF. The RI constitutes a useful, additional tool to facilitate clinicians in choosing DOACs or warfarin in particular category of AF patients.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Atrial Fibrillation | Cardiology | Stroke | Study